Sound Pharmaceuticals   Report issue

For profit Phase 3
Founded: Seattle WA United States (2001)

Organization Overview

First Clinical Trial
2006
NCT01452607
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Sound Pharmaceuticals, Inc. | SOUND PHARMACEUTICALS, INC. | Sound Pharmaceuticals, Incorporated

Active Ingredients

Drugs in Phase 3 Trials (1)

ebselen (11 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bipolar Disorder (Phase 2)

Communicable Diseases (Phase 2)

Coronavirus Infections (Phase 2)

Cystic Fibrosis (Phase 2)

Deafness (Phase 2)

Disease (Phase 2)

Head and Neck Neoplasms (Phase 2)

Hearing Loss (Phase 2)

Hearing Loss, Noise-Induced (Phase 2)

Infections (Phase 2)

Meniere Disease (Phase 3)

Severe Acute Respiratory Syndrome (Phase 2)

Tinnitus (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 1